Literature DB >> 6746894

Immune responses to myelin antigens in Guillain-Barré syndrome.

R A Hughes, I A Gray, N A Gregson, M Kadlubowski, M Kennedy, S Leibowitz, H Thompson.   

Abstract

Antibodies to nerve antigens were sought in the sera of 17 patients with acute Guillain-Barré syndrome (GBS), 11 with chronic relapsing demyelinating poly-radiculoneuropathy (CRP), 20 with other neuropathies (ON), 15 with other neurological diseases (OND) and 19 normal subjects. Complement-fixing antibodies to a suspension of human peripheral nerve tissue were identified in only 2 patients with GBS and 1 with chronic progressive neuropathy. Five GBS sera gave complement fixation reactions with rabbit sciatic nerve. The sera were also tested for galactocerebroside (Gal-C) binding activity using a solid phase assay. The range of values in all groups was the same, although the mean values for patients with GBS, ON and OND were higher than those of normal subjects. In a radioimmunoassay for antibodies to bovine P2 slightly more radiolabelled antigen was precipitated by the GBS group of sera than by sera from the other groups, but only one serum from the GBS and another from the CRP patients precipitated more than 10% of the label. Addition of bovine P2 to cultures of peripheral blood mononuclear cells from 11 patients with GBS did not cause significant stimulation. Immunoassay for antibody to myelin basic protein (MBP) showed an increased proportion of sera with low binding activity in the GBS and CRP groups. The results suggest that humoral immune responses to potentially neuritogenic antigens are found with marginally increased frequency in patients with GBS and CRP.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746894     DOI: 10.1016/0165-5728(84)90019-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Guillain Barré syndrome.

Authors:  J B Winer
Journal:  Mol Pathol       Date:  2001-12

Review 2.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome.

Authors:  G Nakos; E Tziakou; L Maneta-Peyret; C Nassis; M E Lekka
Journal:  Intensive Care Med       Date:  2005-07-26       Impact factor: 17.440

4.  A prospective study of acute idiopathic neuropathy. III. Immunological studies.

Authors:  J B Winer; I A Gray; N A Gregson; R A Hughes; S Leibowitz; P Shepherd; W A Taylor; V Yewdall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

5.  Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a).

Authors:  C M Gabriel; N A Gregson; N W Wood; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

6.  Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy.

Authors:  H R Inglis; P A Csurhes; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-08       Impact factor: 10.154

7.  Molecular mimicry and the autoimmune response to the peripheral nerve myelin P0 glycoprotein.

Authors:  M Adelmann; C Linington
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

8.  Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin.

Authors:  P Fredman; C A Vedeler; H Nyland; J A Aarli; L Svennerholm
Journal:  J Neurol       Date:  1991-04       Impact factor: 4.849

Review 9.  Can antiglycolipid antibodies present in HIV-infected individuals induce immune demyelination?

Authors:  S Petratos; M E Gonzales
Journal:  Neuropathology       Date:  2000-12       Impact factor: 1.906

Review 10.  An update in guillain-barré syndrome.

Authors:  J B Winer
Journal:  Autoimmune Dis       Date:  2014-01-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.